

Uppsala 2019-10-02

Double Bond Pharma signed a distribution agreement with Zoono

Double Bond Pharmaceutical (DBP) has signed an agreement with Zoono for the distribution of selected products in the Scandinavian market. The sale of these products will be handled by its subsidiary Drugsson AB.

Zoono provides cost effective, polymer based, broad-spectrum antimicrobial protection. The products are effective against bacteria, viruses, fungi (mould), yeasts, pathogens incl. MRSA, E.Coli, H1N1, Listeria, TB, black mould, Norovirus etc.

Drugsson will market the products to both consumers (self-care) and healthcare, which shows that the products have a broad market.

"We are pleased to sign an agreement for the distribution of their products," says Igor Lokot, CEO of DBP. - Even more products to our portfolio have now been added and we will continue to acquire more"

More about Zoono: <http://www.zoono.com>

More about Drugsson AB: www.drugsson.com

This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 02 of October 2019.

Full Company Name: Double Bond Pharmaceutical International AB (publ)

Corporate identity: 556991-6082

Stock short name: DBP B

Share ISIN code: SE0007185525

For more info, contact

Igor Lokot, CEO

Homepage: <http://www.doublebp.com/>

E-mail: info@doublebp.com

Blog: <http://blog.doublebp.com>



Follow us on LinkedIn (<https://www.linkedin.com/company/double-bond-pharmaceutical?trk=co-feed-likes-one>) and Twitter (<https://twitter.com/DoubleBondPharm>)!

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company's own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.